Compounded GLP-1 medications cost far less than brand-name options, but they come with trade-offs. This guide explains how compounding works, what the FDA says, safety risks, and who
Compounded GLP-1 medications are custom-made versions of semaglutide and tirzepatide created by specialized pharmacies rather than pharmaceutical manufacturers. They cost $200-$400/month versus $900-$1,400/month for brand-name Ozempic, Wegovy, or Mounjaro—but they haven’t undergone FDA approval, clinical trials, or the same rigorous quality control as brand-name drugs.
Key differences to understand:
Compounded GLP-1s exist in a complicated regulatory space subject to ongoing FDA scrutiny and pharmaceutical company lawsuits. Understanding what they actually are, the real trade-offs, and how to identify legitimate versus questionable pharmacies helps you make an informed decision.
Compounding is the practice of creating customized medications by combining, mixing, or altering ingredients to meet specific patient needs. Compounding pharmacies have existed for decades, originally serving patients who needed custom formulations like dye-free medications, different dosage strengths, or alternative delivery methods not commercially available.
How compounding works for GLP-1s: A compounding pharmacy purchases the active pharmaceutical ingredient (API), in this case semaglutide or tirzepatide in powder form, then reconstitutes it with bacteriostatic water or other solutions to create injectable medications. These are typically provided in multi-dose vials that patients draw from using syringes, though some pharmacies offer pre-filled syringes.
503A vs 503B facilities: The FDA regulates two types of compounding pharmacies under different standards.
503A pharmacies are traditional compounding pharmacies that create patient-specific prescriptions. They must have an individual prescription from a healthcare provider for a specific patient. They’re regulated primarily by state boards of pharmacy and can only compound in small quantities.
503B outsourcing facilities can compound larger batches of medications without patient-specific prescriptions. They register with the FDA and must follow Current Good Manufacturing Practice (CGMP) standards similar to pharmaceutical manufacturers, including more rigorous testing and quality controls. They can distribute to healthcare providers and pharmacies.
Key differences from brand-name: Brand-name Ozempic, Wegovy, and Mounjaro go through extensive FDA approval processes including years of clinical trials, standardized manufacturing under strict CGMP requirements, and ongoing FDA oversight with regular facility inspections. Each dose contains exactly the labeled amount of medication with minimal variation.
Compounded versions skip the FDA approval process entirely. They don’t go through clinical trials. Quality control and testing requirements vary significantly depending on the pharmacy type and state regulations. Potency can vary between batches and even between doses from the same vial.
Why it’s legal but complicated: Under federal law, compounding is legal when a drug is on the FDA’s shortage list. Both semaglutide and tirzepatide have appeared on and off the FDA’s drug shortage database since 2022 due to unprecedented demand. When a drug is in shortage, compounding pharmacies can legally compound it. When the shortage is resolved and the drug is removed from the list, compounding that medication becomes legally questionable.
The FDA’s position on compounded GLP-1s has evolved and remains fluid as of 2026.
FDA’s current stance: The FDA has stated that compounded drugs are not FDA-approved, meaning they haven’t undergone the agency’s evaluation for safety, effectiveness, and quality. In December 2023, the FDA issued a warning specifically about compounded semaglutide products, noting that these products “may not have the same safety, effectiveness, and quality as FDA-approved semaglutide products.”
The agency has expressed particular concern about the proliferation of compounded GLP-1s sold by telehealth companies and online pharmacies, some of which may not be following proper compounding standards. In February 2026, the FDA announced it will be taking legal action against companies like Hims & Hers and other compounding pharmacies.
Shortage provisions: Federal law allows compounding of drugs that are in shortage under specific conditions. The FDA maintains an official drug shortage database. Semaglutide appeared on this list in 2022 and remained there through 2024 due to manufacturing capacity not meeting demand. Tirzepatide was added to the shortage list in 2022 as well.
However, as manufacturers increase production capacity, these medications have been intermittently removed from the shortage list, creating legal uncertainty about compounding. In October 2024, the FDA removed tirzepatide from the shortage list, then restored it following pushback and legal challenges, then removed it again.
Recent regulatory changes: The regulatory landscape shifted significantly in late 2024 and into 2025. Eli Lilly and Novo Nordisk, manufacturers of the brand-name medications, have filed lawsuits against multiple compounding pharmacies and wellness clinics, arguing that compounding these medications violates their patents and endangers patients. And in February 2026, Novo Nordisk sued Hims & Hers over copycat versions of Wegovy weight loss drugs.
The FDA has also increased enforcement actions against compounding pharmacies that violate safety standards or make unsubstantiated claims about their compounded products.
What’s allowed vs prohibited: Compounding pharmacies can legally compound medications on the shortage list for individual patients with valid prescriptions. They cannot mass-produce medications like pharmaceutical manufacturers, advertise compounded drugs directly to consumers (though the companies that use them can), or make claims about efficacy that suggest their products are equivalent to FDA-approved drugs.
They’re prohibited from compounding copies of commercially available drugs that aren’t in shortage. They cannot use salt forms of the drug (like semaglutide sodium) as a workaround to continue compounding when the base drug is removed from the shortage list, though some pharmacies have attempted this.
The safety profile of compounded GLP-1s depends entirely on the specific pharmacy compounding them. This is not a simple “compounded medications are dangerous” or “they’re just as good as brand-name” situation.
Quality control differences: Brand-name medications are manufactured under CGMP requirements with extensive quality control. Every batch undergoes potency testing, sterility testing, endotoxin testing, and particulate matter testing. Manufacturing facilities face regular FDA inspections.
503B outsourcing facilities must follow similar CGMP standards and undergo FDA inspections, though less frequently than pharmaceutical manufacturers. They typically perform batch testing for potency and sterility.
503A pharmacies have less stringent requirements. Testing standards vary by state. Many perform potency testing on batches, but not all do. Some rely on certificates of analysis from their API suppliers without independent verification.
Potency variability risks: The FDA has tested compounded semaglutide products and found significant variability. Some contained much less active ingredient than labeled, while others contained more.
This variability means you might be getting significantly more or less medication than you think. Too little means ineffective treatment. Too much increases side effect risks.
What testing exists: Legitimate compounding pharmacies should provide certificates of analysis showing:
Ask your pharmacy what testing they perform and request to see certificates of analysis. Reputable pharmacies will provide this information.
How to verify a legitimate pharmacy: Check that the pharmacy is licensed in your state. Verify they’re registered as a 503A or 503B facility. For 503B facilities, you can search the FDA’s Outsourcing Facility Database. Look for pharmacies accredited by organizations like the Pharmacy Compounding Accreditation Board (PCAB).
Ask about their testing protocols, where they source their API, and what quality controls they have in place. Legitimate pharmacies will answer these questions transparently.
Red flags to avoid:
Balanced perspective: Many people have used compounded GLP-1s successfully with good results and minimal issues. Reputable compounding pharmacies, particularly 503B facilities, maintain high standards and produce quality products. But the quality is not guaranteed the way FDA-approved medications are, and the oversight is less rigorous. You’re taking on additional risk in exchange for lower cost.
The price difference between compounded and brand-name GLP-1s is the primary reason people choose compounding.
Compounded medications: Typically cost $200-$400 per month depending on the dose and pharmacy. Some telehealth providers offering compounded semaglutide charge as low as $149/month for lower doses, as of February 2026. Higher doses and tirzepatide generally run $300-$400/month. These prices usually include the medication, supplies, and sometimes medical consultations.
Brand-name medications: List prices are $935-$1,349 per month depending on the specific medication. Without insurance coverage, this is what you’ll pay. With insurance, costs vary wildly. Some people pay $25/month with good coverage. Others hit high deductibles and pay full price until they meet them. Many insurance plans don’t cover GLP-1s for weight loss at all.
Why the difference: Brand-name manufacturers spent billions on research, development, and clinical trials. They’re recouping those costs and making profit. Compounding pharmacies purchase the active ingredient in bulk and avoid the development costs. They also have lower regulatory compliance costs and can operate with smaller profit margins.
What you sacrifice for savings: You’re giving up the FDA’s guarantee of safety, efficacy, and quality. You’re accepting more variability in potency. You’re using a product that hasn’t been tested in clinical trials. You may have less legal recourse if something goes wrong. Customer support and medical oversight may be less comprehensive than through pharmaceutical companies’ patient programs.
Pros:
Cons:
Compounded GLP-1 medications occupy a complicated middle ground. They’re not outright dangerous, but they’re not as rigorously tested and regulated as FDA-approved drugs. They provide access to life-changing medication for people who can’t afford or access brand-name versions, but they come with real trade-offs.
Who might consider compounded versions:
Importance of medical supervision: Whether you choose brand-name or compounded, work with a qualified healthcare provider who monitors your progress, manages side effects, and ensures the medication is appropriate for you. Avoid companies that provide medication with minimal medical oversight.
Get regular follow-ups. Track your results. If something doesn’t feel right or your weight loss stalls unexpectedly, consider whether potency variability might be a factor.
The informed decision framework: Understand what you’re getting, what you’re giving up, and what risks you’re accepting. Don’t assume compounded medications are “just as good” as brand-name or that all compounding pharmacies are equal. Research the specific pharmacy. Ask questions. Request documentation.
For some people, the cost savings make compounded medications the only viable option. For others, the peace of mind from FDA-approved medications is worth the higher price. Both are valid choices when made with full understanding of the trade-offs.
